Adlai Nortye Ltd. (NASDAQ:ANL – Get Free Report) saw a large growth in short interest during the month of January. As of January 15th, there was short interest totalling 6,800 shares, a growth of 112.5% from the December 31st total of 3,200 shares. Based on an average trading volume of 16,400 shares, the days-to-cover ratio is currently 0.4 days.
Adlai Nortye Stock Up 3.2 %
NASDAQ:ANL traded up $0.07 during mid-day trading on Friday, reaching $2.13. The company’s stock had a trading volume of 1,603 shares, compared to its average volume of 11,598. Adlai Nortye has a 1 year low of $1.85 and a 1 year high of $17.48. The stock has a fifty day moving average of $2.18 and a 200-day moving average of $2.47.
Analyst Ratings Changes
Separately, HC Wainwright reissued a “buy” rating and set a $9.00 target price on shares of Adlai Nortye in a research note on Monday, November 11th.
Adlai Nortye Company Profile
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.
Further Reading
- Five stocks we like better than Adlai Nortye
- What Are Some of the Best Large-Cap Stocks to Buy?
- The Best Way to Invest in Gold Is…
- Airline Stocks – Top Airline Stocks to Buy Now
- Why Nike Stock Could Be 2025’s Top Comeback Play
- How to Short Nasdaq: An Easy-to-Follow Guide
- Uber Stock Gaining Speed: Analysts See 30% Upside
Receive News & Ratings for Adlai Nortye Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adlai Nortye and related companies with MarketBeat.com's FREE daily email newsletter.